Navigation Links
Ethicon Endo-Surgery Unveils Full Energy Portfolio for First Time at American College of Surgeons Clinical Congress
Date:10/12/2009

CHICAGO, Oct. 12 /PRNewswire/ -- Ethicon Endo-Surgery, Inc., today unveiled its broad portfolio of energy delivery devices at the 95th Annual Clinical Congress of the American College of Surgeons (ACS). The complementary energy technologies of worldwide leading HARMONIC® ultrasonic and ENSEAL® advanced bipolar devices provide surgeons with multiple energy delivery options that provide superior energy application for desired tissue effects to meet specific surgical needs across multiple surgical specialties. Ethicon Endo-Surgery acquired the ENSEAL® technology in October 2008; the ACS Annual Clinical Congress marks the full integration of the ENSEAL® product line into the Ethicon Endo-Surgery energy portfolio.

"I believe energy is the future of surgery, which is why we're seeing such significant advances in both bipolar and ultrasonic energy, which enhance the experience of surgeons and patients alike," said Michael J. Stamos, MD, FACS, FASCRS, chief, Division of Colon & Rectal Surgery, Department of Surgery, University of California, Irvine. "Since each patient case is unique, it is imperative to understand the distinctive attributes of each different energy technology. It also is critical to have the confidence and flexibility to choose the right modality to achieve optimal outcomes for both patients and for surgeons in terms of greater precision and control, maximized surgical efficiency and best tissue effect."

As energy delivery device options have evolved, they have enabled more efficient and minimally invasive surgical techniques. Ethicon Endo-Surgery, originally with HARMONIC® technology and now ENSEAL®, has led this evolution of surgery by working directly with surgeons to develop innovations, enabling greater functionality, controlled tissue sealing, and minimization of tissue trauma.

With its bipolar technology, ENSEAL® offers superior control in large vessel sealing for surgical procedures in general, colorectal, gynecology, and urology where minimal tissue damage is critical. Pre-clinical studies have shown ENSEAL® laparoscopic and open devices contain energy spread and are faster at sealing and transecting than competitive devices, while offering exceptional large vessel sealing (up to and including 7mm blood vessels).

As the leading ultrasonic cutting and coagulating surgical device used in more than 8 million surgical procedures worldwide since 1995, HARMONIC® allows precise application of ultrasonic energy in advanced laparoscopic and open procedures, and minimizes adjacent tissue damage to the patient. These devices are versatile and help the surgeon perform multiple surgical tasks with a single device that can lead to overall efficiency improvement over traditional techniques. HARMONIC® is indicated for multiple specialties and surgeries, including laparoscopic and open technique procedures within general, colorectal, gynecologic and urologic procedures, and often is credited with being the first device to enable some advanced laparoscopic procedures that general surgeons perform today.

"An increasing number of surgeons are applying the new technologies as standard of care for both laparoscopic and open procedures," said Kevin Lobo, worldwide president, Ethicon Endo-Surgery. "By offering both an ultrasonic and advanced bipolar technology, Ethicon Endo-Surgery delivers options to meet the needs of traditional and emerging surgical techniques."

About Ethicon Endo-Surgery

Ethicon Endo-Surgery develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at www.ethiconendo.com.

SOURCE Ethicon Endo-Surgery, Inc.


'/>"/>
SOURCE Ethicon Endo-Surgery, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
2. First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
3. Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM)
4. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
5. Oregon Tourism Commission Unveils New Online Customer Service Training Program
6. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
7. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
8. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
9. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
10. Boehringer Ingelheim Unveils Diabetes Pipeline
11. GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  BERG, a biopharmaceutical company uncovering ... approach, today announced that the company,s Interrogative ... new data using a cold-induced model to ... Joslin Diabetes Center led the investigation with ... analysis of samples.  The findings were published ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... mixed colors as the NASDAQ Composite closed the trading ... 0.29% lower; and the S&P 500 was down 0.08%. ... of nine sectors finishing the day in green. Pre-market ... stocks: Wright Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the ... , “There were things that his parents and teachers had asked of him that he ... he was going to defy the Almighty Creator. There were some who would have felt ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Bruce Trimble ... without requiring a referral. Trimble Dental offers a variety of services to ... dental implants. Whether patients have discolored, crooked or missing teeth in Eau Claire, ...
(Date:3/27/2017)... ... March 27, 2017 , ... This is the second major ... in 2014. It is the culmination of collaborative efforts by members of ... OSEHRA Organizational Member Zato Health co-funded the ONC certification and provided key technical ...
(Date:3/27/2017)... Boston, MA (PRWEB) , ... March 27, 2017 ... ... NEJM Group, the organization behind the New England Journal of Medicine and NEJM ... , NEJM Knowledge+ Pediatrics Board Review was created by a panel of pediatricians ...
Breaking Medicine News(10 mins):